| About
75% of all skin cancer related deaths in the United States are the result of melanoma.
Since 1973 the incidence of this disease in the United States has increased at a rate of
about 4% per year, increasing to 6% in 1999. The incidence of melanoma is now increasing
faster than any other cancer in the United States. Approximately 47,500 Americans
developed new cases of cutaneous melanoma in 1999, and 7,400 died of the disease. It is
now estimated that nearly 1 in 75 Americans will develop this cancer in their lifetime.
Primary risk factors for melanoma include lightly pigmented skin, history of sunburn
events in youth, family history of melanoma, presence of a large number, i.e. >100, of
moles, and presence of dysplastic nevi or atypical moles. In contrast to most skin
cancers, melanoma has a strong tendency to become invasive and metastasize. Because there
is no good treatment for metastatic melanoma, even small cancers often prove fatal if not
detected early. Melanoma allowed to invade the subcutaneous tissue is associated with a
five-year survival of only 44%. As a consequence, the problems posed by its rising
incidence have been especially severe. The irony of these grim statistics is that few
cancers provide a greater opportunity for early discovery and cure. Cutaneous melanoma is
not only located in the open where it is readily observed, but typically undergoes a
"radial growth" phase prior to metastasis. Radial growth is a specific
biological phase of development rather than a geometric description. Cells actually grow
in all directions from a malignant focus, but those growing toward the skin surface slough
off, while those attempting to invade the dermis are destroyed by immune surveillance.
Thus the net growth is superficial and circumferential, gradually increasing the area of
the lesion and changing its coloration.
For the early detection of melanoma screening measures must focus on two primary tasks:
1) detection of lesion changes indicative of the radial-growth stage of malignancy and 2)
alerting the patient and physician to the existence of a new lesion on the skin. In
practice this is a frustratingly difficult challenge. The typical scenario is that a high
risk patient is charged with personally monitoring his or her own skin lesions with an eye
out for change. When the patient sees a physician the patient is then asked to identify
any changed lesions. The Western Research Company, Inc. experience after more than five
years of working with a specific population of high risk patients with a large number of
moles or dysplastic nevi is that they have nearly given up trying to follow changes. The
problems they most frequently cite are the following: 1) "I have too many moles to be
able to follow them.", 2) "I can't see most of my moles." (i.e. they are on
parts of the body not readily viewable), and 3) "I try to follow my moles, but I am
not always certain whether they are new or not."
There have been several studies which indicate the importance, not only of
dermatological screening, but of whole body dermatological screening. In fact, the above
referenced New York City screening program concluded that over 90% of the malignant
melanomas found would have been missed in partial, as opposed to whole body, screening.
Implementing a screening program which encourages and facilitates effective whole body
screening would represent a significant improvement in public health.
Western Research Company, Inc. has developed DermAlert®, a microcomputer based
digital imaging system which has been optimized for early detection of new and changed
skin lesions. This is an easy to use system which allows the capture of registered pairs
of images of the skin (as obtained in two or more examinations typically separated in time
by months or years), and to alternately display those images on a computer monitor at a
user selected frequency .
When these registered images are alternately displayed, or "blinked", there
is a remarkably strong visual impression of any change in the images. Those moles and
lesions which have not changed during the intervening time period between the two image
captures, appear unchanged in the images. A new feature, however, will appear to flash in
the image, literally blinking on and off. It has been our experience that even very low
contrast features are highly detectable by this appearance. On the other hand, those
lesions or features which have changed size in the interim, appear to "pulsate"
in the image display. This is also a highly stimulating visual cue. It is the remarkable
ease with which changed lesions can be identified with this type of approach that makes it
particularly intriguing as a screening tool. |